Catalyst

Slingshot members are tracking this event:

Regeneron Pharmaceuticals (REGN) Phase 2 PD-1 antibody trial in non-small cell lung cancer set to begin in 2017

Source Link:
http://files.shareholder.com/downloads/REGN/4667936278x0x942278/319BFC54-AE86-45FC-8B5D-8E9E6EDD40B5/REGN_Corp_Presentation_jun2017.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
REGN Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 13, 2017
Occurred Source:
http://files.shareholder.com/downloads/REGN/5250934809x0x966618/7AEDA08B-6093-48ED-8483-744E18D1AB5D/REGN_News_2017_12_13_General_Releases.pdf
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Non-small Cell Lung Cancer, Pd-1, Phase 2
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.